SciMed Biotech Podcast with Mark Frohlich

From Provenge to Next-Gen NK Cells Building the Future of Cellular Immunotherapy

What if the next generation of cancer and autoimmune treatments came from naturally occurring immune cells, ready to be administered without delay, and without the dangerous side effects of traditional therapies?

In this episode of the SciMed Biotech Podcast, we sit down with Dr. Mark Frohlich, CEO of Indapta Therapeutics, to explore just that. With a career spanning over two decades at the forefront of cellular immunotherapy—from developing Provenge, the first FDA-approved therapeutic cancer vaccine, to now leading one of the most exciting NK cell platforms in biotech—Mark shares a rare insider’s view of how the field has evolved and where it’s going.

We dive deep into Indapta’s breakthrough approach to natural killer (NK) cells—specifically G-minus NK cells sourced from healthy donors—and why this "off-the-shelf" cell therapy could fundamentally shift how and where patients are treated.

If you’re curious about how real clinical results are reshaping the future of cancer and autoimmune care, or what it takes to bring a new class of therapies to market, this conversation is packed with insight.